REVOLUTION MEDICINES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.96 USD | +1.78% |
|
+2.98% | +25.38% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,628 | 1,855 | 2,115 | 4,720 | 6,131 | - | - |
| Enterprise Value (EV) 1 | 2,628 | 1,278 | 1,470 | 2,867 | 4,733 | 5,265 | 5,876 |
| P/E ratio | -19.7 x | -9.79 x | -7.73 x | -7.43 x | -11.3 x | -10.5 x | -10.6 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 61.1 x | 63.1 x | 59.8 x | 408 x | 1,327 x | 1,690 x | 222 x |
| EV / Revenue | 61.1 x | 43.5 x | 41.6 x | 248 x | 1,024 x | 1,451 x | 213 x |
| EV / EBITDA | -24.3 x | -6.91 x | -5.81 x | -5.96 x | -8.02 x | -8.79 x | -8.16 x |
| EV / FCF | -25.5 x | -8.31 x | -6.25 x | -8 x | -10.8 x | -11 x | -12.1 x |
| FCF Yield | -3.92% | -12% | -16% | -12.5% | -9.26% | -9.12% | -8.28% |
| Price to Book | 4.58 x | 3.1 x | 3.14 x | 1.78 x | 4.32 x | 5.86 x | 11 x |
| Nbr of stocks (in thousands) | 66,380 | 73,687 | 88,791 | 164,565 | 170,493 | - | - |
| Reference price 2 | 39.59 | 25.17 | 23.82 | 28.68 | 35.96 | 35.96 | 35.96 |
| Announcement Date | 3/2/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 50.04 | 42.98 | 29.39 | 35.38 | 11.58 | 4.621 | 3.627 | 27.59 |
| EBITDA 1 | - | -108.1 | -184.9 | -253.2 | -481.1 | -589.9 | -599.3 | -719.8 |
| EBIT 1 | -54.12 | -110.7 | -188 | -258.3 | -487.2 | -588.6 | -601.8 | -610.5 |
| Operating Margin | -108.15% | -257.54% | -639.7% | -730.01% | -4,207.12% | -12,739.19% | -16,591.31% | -2,212.29% |
| Earnings before Tax (EBT) 1 | -52.04 | -108.5 | -187.1 | -249.1 | -439.9 | -519.6 | -564.3 | -564.3 |
| Net income 1 | -61.9 | -110.4 | -187.1 | -248.7 | -436.4 | -516.4 | -561.7 | -577.3 |
| Net margin | -123.7% | -256.8% | -636.58% | -702.95% | -3,768.28% | -11,175.07% | -15,485.49% | -2,092.18% |
| EPS 2 | -1.049 | -2.010 | -2.570 | -3.080 | -3.860 | -3.192 | -3.427 | -3.399 |
| Free Cash Flow 1 | -52.2 | -103 | -153.7 | -235.2 | -358.3 | -438.1 | -480.2 | -486.6 |
| FCF margin | -104.32% | -239.62% | -522.99% | -664.83% | -3,094.14% | -9,481.96% | -13,238.79% | -1,763.4% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/2/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.101 | 9.46 | 7.578 | 9.116 | 3.356 | 15.33 | 7.014 | 3.824 | - | 0.742 | 0.6742 | 0.6742 | 0.6742 | 0.6742 | 0.2333 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -178.4 | -160.4 | -163.2 | -168.2 | -170.7 | -176.6 |
| EBIT 1 | -53.16 | -52.91 | -57.95 | -62.09 | -76.53 | -61.71 | -75.16 | -108.8 | -123.2 | -180 | -140.5 | -145.3 | -152.3 | -157.6 | -162.2 |
| Operating Margin | -4,828.61% | -559.33% | -764.7% | -681.1% | -2,280.48% | -402.52% | -1,071.53% | -2,845.11% | - | -24,256.47% | -20,832.81% | -21,552.47% | -22,590.79% | -23,379.84% | -69,511.16% |
| Earnings before Tax (EBT) 1 | -52.94 | -52.68 | -57.65 | -61.22 | -73.63 | -56.63 | -68.1 | -98.3 | -112.3 | -161.2 | -120 | -125.8 | -134.2 | -140.9 | -139.3 |
| Net income 1 | -52.94 | -52.68 | -57.65 | -61.22 | -73.33 | -56.51 | -68.1 | -98.3 | -108.4 | -161.5 | -121 | -126.3 | -133.7 | -139.8 | -141.1 |
| Net margin | -4,808.36% | -556.83% | -760.72% | -671.58% | -2,185.01% | -368.6% | -970.89% | -2,570.55% | - | -21,770.49% | -17,940.8% | -18,729.21% | -19,834.91% | -20,733.7% | -60,456.98% |
| EPS 2 | -0.7200 | -0.7100 | -0.7800 | -0.8200 | -0.8700 | -0.6300 | -0.7200 | -0.9200 | -0.9900 | -1.140 | -0.7466 | -0.7766 | -0.8198 | -0.8498 | -0.8685 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/28/22 | 5/9/22 | 8/9/22 | 11/7/22 | 2/27/23 | 5/8/23 | 8/8/23 | 11/6/23 | 2/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 123 | - | 577 | 645 | 1,853 | 1,398 | 866 | 255 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -52.2 | -103 | -154 | -235 | -358 | -438 | -480 | -487 |
| ROE (net income / shareholders' equity) | - | -68.5% | -34.7% | -38.6% | -34.8% | -30.6% | -49.3% | -96.9% |
| ROA (Net income/ Total Assets) | -31.7% | -28% | -28.7% | -32.1% | -30.4% | -27.8% | -35.2% | -48.9% |
| Assets 1 | 195.6 | 394 | 652.7 | 774.5 | 1,436 | 1,856 | 1,597 | 1,181 |
| Book Value Per Share 2 | -2.590 | 8.650 | 8.130 | 7.580 | 16.10 | 8.320 | 6.140 | 3.280 |
| Cash Flow per Share 2 | - | - | - | - | -3.100 | -3.000 | -3.240 | - |
| Capex 1 | 2.59 | 2.93 | 6.53 | 10.8 | 7.73 | 9.36 | 10.2 | 11.3 |
| Capex / Sales | 5.17% | 6.82% | 22.21% | 30.57% | 66.74% | 202.58% | 280.34% | 41.08% |
| Announcement Date | 3/30/20 | 3/2/21 | 2/28/22 | 2/27/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
35.96
USD
Average target price
41.62
USD
Spread / Average Target
+15.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.38% | 6.13B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- RVMD Stock
- Financials Revolution Medicines, Inc.
